Literature DB >> 10775582

Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes.

C Berger1, S Xuereb, D C Johnson, K S Watanabe, H P Kiem, P D Greenberg, S R Riddell.   

Abstract

The in vivo persistence of gene-modified cells may be limited by the development of a host immune response to vector-encoded proteins. Herpesviruses evade cytotoxic T-lymphocyte (CTL) recognition by expressing genes which interfere selectively with presentation of viral antigens by class I major histocompatibility complex (MHC) molecules. Here, we studied the use of retroviral vectors encoding herpes simplex virus ICP47, human cytomegalovirus (HCMV) US3, or HCMV US11 to decrease presentation of viral proteins and transgene products to CD8(+) CTL. Human fibroblasts and T cells transduced to express the ICP47, US3, or US11 genes alone exhibited a decrease in cell surface class I MHC expression. The combination of ICP47 and US11 rendered fibroblasts negative for surface class I MHC and allowed a class I MHC-low population of T cells to be sorted by flow cytometry. Fibroblasts and T cells expressing both ICP47 and US11 were protected from CTL-mediated lysis and failed to stimulate specific memory T-cell responses to transgene products in vitro. Our findings suggest that expression of immunoregulatory viral gene products could be a potential strategy to prolong transgene expression in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775582      PMCID: PMC111967          DOI: 10.1128/jvi.74.10.4465-4473.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  A viral inhibitor of peptide transporters for antigen presentation.

Authors:  K Früh; K Ahn; H Djaballah; P Sempé; P M van Endert; R Tampé; P A Peterson; Y Yang
Journal:  Nature       Date:  1995-06-01       Impact factor: 49.962

2.  A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes.

Authors:  I A York; C Roop; D W Andrews; S R Riddell; F L Graham; D C Johnson
Journal:  Cell       Date:  1994-05-20       Impact factor: 41.582

3.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.

Authors:  Y Yang; Q Li; H C Ertl; J M Wilson
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

4.  Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.

Authors:  E McLaughlin-Taylor; H Pande; S J Forman; B Tanamachi; C R Li; J A Zaia; P D Greenberg; S R Riddell
Journal:  J Med Virol       Date:  1994-05       Impact factor: 2.327

5.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

Authors:  J F Engelhardt; X Ye; B Doranz; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

6.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

Authors:  Y Dai; E M Schwarz; D Gu; W W Zhang; N Sarvetnick; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

7.  Herpes simplex virus turns off the TAP to evade host immunity.

Authors:  A Hill; P Jugovic; I York; G Russ; J Bennink; J Yewdell; H Ploegh; D Johnson
Journal:  Nature       Date:  1995-06-01       Impact factor: 49.962

8.  Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains.

Authors:  T R Jones; L K Hanson; L Sun; J S Slater; R M Stenberg; A E Campbell
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice.

Authors:  T Zhumabekov; P Corbella; M Tolaini; D Kioussis
Journal:  J Immunol Methods       Date:  1995-09-11       Impact factor: 2.303

10.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

Authors:  C M Rooney; C A Smith; C Y Ng; S Loftin; C Li; R A Krance; M K Brenner; H E Heslop
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

View more
  6 in total

1.  Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model.

Authors:  C Berger; M L Huang; M Gough; P D Greenberg; S R Riddell; H P Kiem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

Authors:  Carolina Berger; Mary E Flowers; Edus H Warren; Stanley R Riddell
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

3.  Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.

Authors:  Hiroki Torikai; Andreas Reik; Frank Soldner; Edus H Warren; Carrie Yuen; Yuanyue Zhou; Denise L Crossland; Helen Huls; Nicholas Littman; Ziying Zhang; Scott S Tykodi; Partow Kebriaei; Dean A Lee; Jeffrey C Miller; Edward J Rebar; Michael C Holmes; Rudolf Jaenisch; Richard E Champlin; Philip D Gregory; Laurence J N Cooper
Journal:  Blood       Date:  2013-06-05       Impact factor: 22.113

Review 4.  Cancer immunotherapy: the beginning of the end of cancer?

Authors:  Sofia Farkona; Eleftherios P Diamandis; Ivan M Blasutig
Journal:  BMC Med       Date:  2016-05-05       Impact factor: 8.775

Review 5.  Oncolytic Viral Therapy for Mesothelioma.

Authors:  Daniel F Pease; Robert A Kratzke
Journal:  Front Oncol       Date:  2017-08-24       Impact factor: 6.244

Review 6.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.